Diferencia entre revisiones de «Vigabatrina»
Contenido eliminado Contenido añadido
listaref |
|||
| Línea 39: | Línea 39: | ||
{{listaref|2}} |
{{listaref|2}} |
||
==Indications== |
==Indications== |
||
=== |
===Epilepsia=== |
||
In Canada, vigabatrin is approved for use as an adjunctive treatment (with other drugs) in treatment resistant [[epilepsy]], [[complex partial seizure]]s, [[seizures|secondary generalized seizures]], and for monotherapy use in [[infantile spasm]]s in [[West syndrome]].<ref name=what_is_vigabatrin/> |
|||
As of 2003, vigabatrin is approved in Mexico for the treatment of epilepsy that is not satisfactorily controlled by conventional therapy (adjunctive or monotherapy) or in recently diagnosed patients who have not tried other agents (monotherapy).<ref name=mexicanuses>[http://www.facmed.unam.mx/bmnd/plm/mex/productos/10130.htm DEF MEXICO: SABRIL] ''Diccionario de Especialdades Farmaceuticas.'' Edicion 49, 2003.</ref> |
|||
Vigabatrin is also indicated for monotherapy use in secondarily generalized [[tonic-clonic seizure]]s, [[seizures|partial seizure]]s, and in infantile spasms due to West syndrome.<ref name=mexicanuses/> |
|||
Revisión del 18:18 3 ene 2011
Vigabatrina es un agente antiepileptico que inhibe el catabolismo del GABA por inhibición de la transaminasa GABA. Es una análogo de GABA, pero no es un agonista del receptor.[1] It is sold under the brand name Sabril.
- ↑ Long, Phillip W. "Vigabatrin." Internet Mental Health. 1995–2003.